A new method, called “prime editing,” could, in principle, correct around
89 percent of the mutations that cause inherited human disease.
A less error-prone DNA editing method could correct many more harmful mutations than was previously possible.
Andrew Anzalone was restless. It was late fall of 2017. The year was winding down, and so was his MD/PhD program at Columbia. Trying to figure out what was next in his life, he’d taken to long walks in the leaf-strewn West Village. One night as he paced up Hudson Street, his stomach filled with La Colombe coffee and his mind with Crispr gene editing papers, an idea began to bubble through the caffeine brume inside his brain.